Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.

Moore, Timothy D.; Phillips, Paulina; Nerenstone, Stacy; Cheson, Bruce D.

doi:10.1200/jco.1991.9.6.1071

Cited by 104 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has also been postulated that agents augmenting the PgR concentration, such as tamoxifen, may potentiate the effectiveness of progestin-based therapy [51]. Tamoxifen has been associated with a 10%-22% response rate in the treatment of endometrial cancer [53,54]. Most studies have correlated response rates to hormonal agents with tumor grade [47,55,56].…”

Section: Combination Hormonal Therapymentioning

confidence: 99%

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Rauh‐Hain

Carmen

2010

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the role of radiation therapy for advanced stage endometrial cancer in order to differentiate between patients who should receive only radiation therapy and patients requiring surgery and/or chemotherapy in addition to radiation.2. Evaluate the role of surgery for stage IV and recurrent endometrial cancer in order to select patients most likely to benefit from cytoreductive surgery.3. Evaluate the role of chemotherapy, particularly in conjunction with radiotherapy, in advanced stage endometrial carcinoma and select appropriate candidates for multimodality therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTWomen with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Depending on previous treatment, women with recurrent endometrial cancer may be appropriate candidates for surgery, radiation therapy, hormonal therapy, or chemotherapy. Women with advanced stage disease at presentation may also be appropriate candidates for systemic and local therapies. We review the treatment options available to treat recurrent and locally advanced endometrial cancer. Treatment choice depends largely on the localization of disease, the patient's performance status and previ-

show abstract

Section: Combination Hormonal Therapymentioning

confidence: 99%

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Rauh‐Hain

Carmen

2010

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Both single-agent and combination regimens of chemotherapy have been studied in women with advanced endometrial carcinoma. Currently, no standard chemotherapy regimen for endometrial cancer exists, but single-agent doxorubicin is active, with responses observed in up to one-third of previously untreated patients (Moore et al, 1991). Other single agents with modest activity include cisplatin (Thigpen et al, 1984a(Thigpen et al, , 1989 and carboplatin (van Wijk et al, 2003).…”

mentioning

confidence: 99%

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

et al. 2005

View full text Add to dashboard Cite

The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status p2 entered the study. Docetaxel 70 mg m À2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39 -74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1 -50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3 -4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

show abstract

“…Although this type of treatment produces high response rates, the duration of response is disappointingly short, and median survival is less than 1 year. Doxorubicin and cisplatin are the most effective drugs, and response rates of up to 42% have been reported [1, 2, 3]. Carboplatin has also definite activity in endometrial carcinoma with response rates ranging from 28 to 33% [4, 5, 6].…”

Section: Introductionmentioning

confidence: 99%

“…Progestins have been the common initial treatment for metastatic disease for the past 30 years, but they are only effective in approximately 15–20% of patients [11]. Phase II studies using multiagent chemotherapy in combination with progestational agents have reported response rates of approximately 50% [12, 13, 14].…”

Section: Introductionmentioning

confidence: 99%

Carboplatin, Methotrexate and 5-Fluorouracil in Combination with Medroxyprogesterone Acetate (JMF-M) in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Hellenic Cooperative Oncology Group Study

et al. 1999

View full text Add to dashboard Cite

Twenty-three patients with advanced or recurrent endometrial carcinoma entered a prospective study of chemotherapy which consisted of carboplatin (300 mg/m²), methotrexate (30 mg/m²), and 5-fluoruracil (500 mg/m²) given on day 1, in a 3-weekly schedule, in combination with medroxyprogesterone acetate (MPA): 300 mg daily, p.o., until progression (JMF-M regimen). None had received prior chemotherapy and/or hormonotherapy for metastatic disease. Ten patients had received radiotherapy. Response to treatment was evaluated every two courses. Objective response was seen in 17 of the 23 patients (74%, 95% confidence interval = 52–90%), with 2 long-lasting complete responses (9%). The median response duration was 10+ months (3–45+). The median survival was 16+ months (2–45+). The 2 complete responders, the first in the lung and the second in groin nodes, are without evidence or recurrence after 32 and 45 months, respectively. The regimen was given on an outpatient basis and was well tolerated. The major toxic effects were myelosuppression (less than 14% leukopenia, anemia and thrombocytopenia). The MPA-related side effects were: weight gain (22%), hypertension (17%) and thromboplebitis (17%). In 2 patients, consolidation treatment with MPA was discontinued because of thromboplebitis. In conclusion, the JMF-M regimen is highly active with an acceptable toxicity in patients with recurrent or metastatic endometrial carcinoma.

show abstract

Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions.

Cited by 104 publications

References 0 publications

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

Carboplatin, Methotrexate and 5-Fluorouracil in Combination with Medroxyprogesterone Acetate (JMF-M) in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Hellenic Cooperative Oncology Group Study

Contact Info

Product

Resources

About